SFDA Expedited Review Oncology Drugs: What You Need to Know

Key Takeaways

• Three-tiered framework: SFDA Priority Review (Guidance v5.3, February 2024) applies to drugs treating serious conditions. Breakthrough Medicine designation (Guidance v1.1, October 2023) requires demonstration of major advantage over existing therapies. RAID designation (Guidance v1.0, April 2026) accelerates development of innovative drugs with Saudi-based clinical trials.
• Breakthrough Medicine criteria: Four mandatory requirements per SFDA guidance: (1) serious condition with unmet need, (2) major advantage over current methods, (3) positive benefit-risk balance, and (4) no prior registration with any regulatory authority.
• Recent approvals: SFDA approved Elrexfio (elranatamab) for multiple myeloma with 58% overall response rate in MagnetisMM-3 trial, and granted world-first approval for Anktiva (nogapendekin alfa inbakicept) in metastatic NSCLC based on QUILT-3.055 trial data.
• RAID implementation: The RAID designation takes effect July 2, 2026, offering enhanced regulatory engagement for investigational drugs developed through Saudi-based research, including priority scientific advice and expedited clinical trial authorization.
• Strategic alignment: These pathways support Saudi Vision 2030's Health Sector Transformation Program objectives to enhance healthcare quality and accelerate access to innovative therapies.

What Is the SFDA Expedited Review Framework?

The Saudi Food and Drug Authority (SFDA) established expedited review pathways to reduce regulatory timelines for oncology drugs addressing serious conditions. Cancer ranks among the leading causes of mortality in Saudi Arabia. Faster approval processes translate directly to earlier patient access to therapies that may improve survival or quality of life.

The framework operates on three levels. Priority Review forms the foundation. Breakthrough Medicine designation adds enhanced regulatory engagement. RAID designation, introduced in 2026, provides the most intensive support for innovative therapies developed within Saudi Arabia. Each pathway maintains full safety and efficacy standards while compressing administrative timelines.

SFDA Priority Review: The Foundation

Priority Review applies to new drugs, biologics, and biosimilars intended to treat serious or life-threatening conditions. The SFDA Priority Review Guidance v5.3 (issued February 11, 2024) defines eligibility criteria. Drugs must address unmet medical needs in serious conditions.

Key requirements include:

• The drug treats a serious or life-threatening condition
• It demonstrates potential to address unmet medical needs
• For biosimilars, the reference product must meet priority criteria

Applicants may request Priority Review designation during development. The SFDA evaluates the request based on clinical data and development plans. Designation allows the drug to proceed through accelerated review timelines upon submission.

Breakthrough Medicine Designation: Enhanced Engagement

The Breakthrough Medicine Program began under SFDA Guidance v1.1 (April 30, 2024). It helps develop drugs that show major improvement over current treatments. The program emphasizes early talks between drug sponsors and SFDA reviewers.

Eligibility Criteria for Breakthrough Medicine

All four criteria must be satisfied:

1. Serious condition with unmet need: The drug targets a debilitating or life-threatening disease where current treatments are inadequate
2. Major advantage: Preliminary clinical evidence suggests the drug offers significant improvement over existing methods
3. Positive benefit-risk: Potential adverse effects are outweighed by anticipated benefits
4. No prior registration: The product has not received marketing authorization from any regulatory authority at submission time

The SFDA scientific committee reviews designation requests within 30 working days. Approved designations receive enhanced regulatory interaction, including priority access to scientific advice and expedited review upon marketing application submission.

RAID Designation: Innovation Incentive

The RAID (Research and Investigational Drugs) designation began April 2, 2026. It takes effect July 2, 2026. RAID is SFDA's newest expedited pathway. It targets new drugs developed through Saudi-based research and clinical trials.

RAID Eligibility Requirements

To qualify for RAID designation, applicants must meet all criteria:

• The product is under active development
• It has not received marketing authorization from any global regulatory authority
• Clinical trials are conducted in Saudi Arabia
• The sponsor intends to submit a Marketing Authorization Application to SFDA

The name "Rā'id" (رائد) reflects pioneering and innovation. RAID designation provides incentives including pre-designation meetings, expedited clinical trial authorization, and priority review of marketing applications.

Recent Oncology Approvals Through Expedited Pathways

The SFDA has approved multiple oncology therapies through these expedited programs in 2024-2026.

Elrexfio for Multiple Myeloma

On July 2, 2026, SFDA approved Elrexfio (elranatamab) for relapsed or refractory multiple myeloma. The approval covers adult patients who received at least four prior lines of therapy, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.

Elranatamab is a bispecific antibody targeting BCMA on myeloma cells and CD3 on T-cells. The MagnetisMM-3 Phase 2 trial (NCT04649359) demonstrated:

• 58% overall response rate in heavily pretreated patients
• 82% of responders maintained response for at least nine months
• Subcutaneous administration with step-up dosing

SFDA granted Elrexfio orphan drug designation, which provides additional incentives for rare disease therapies affecting fewer than five individuals per 10,000 in Saudi Arabia.

Anktiva: World-First NSCLC Approval

On January 14, 2026, SFDA granted conditional approval for Anktiva (nogapendekin alfa inbakicept)—the first regulatory authority globally to approve this IL-15 receptor agonist for metastatic non-small cell lung cancer (NSCLC). The approval applies to patients whose disease progressed after standard-of-care therapy including immune checkpoint inhibitors.

The approval decision drew on data from two clinical trials:

• QUILT-3.055: Single-arm study in checkpoint-experienced NSCLC patients showing immune restoration and survival association
• QUILT-2.023: Randomized trial demonstrating biological activity in restoring lymphocyte counts

Anktiva activates natural killer (NK) cells, CD4+ T cells, CD8+ T cells, and memory T cells through IL-15 receptor binding. For NSCLC, it is administered subcutaneously in combination with checkpoint inhibitors.

SFDA also approved Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, based on QUILT-3.032 trial data showing 62% complete response rate.

How Do SFDA Pathways Compare to FDA Programs?

Comparison of Expedited Review Programs: SFDA vs FDA

SFDA Program	FDA Equivalent	Key Similarity	Key Difference
Priority Review	Priority Review	Accelerated timeline for serious conditions	SFDA allows biosimilar priority review
Breakthrough Medicine	Breakthrough Therapy	Requires evidence of substantial improvement	SFDA requires no prior global registration
RAID Designation	No direct equivalent	Expedited development and review	RAID requires Saudi-based clinical trials
Orphan Drug Program	Orphan Drug Designation	Incentives for rare disease therapies	SFDA threshold: <5 per 10,000 population

Both agencies prioritize drugs that fill unmet needs in serious conditions. The FDA offers Fast Track and Accelerated Approval programs. These differ in process from SFDA pathways. Yet both share the same core goal. They balance speed with scientific rigor.

What Should Developers Consider When Selecting a Pathway?

Pharmaceutical companies should weigh clinical data, market position, and development plans when choosing an SFDA expedited pathway.

Priority Review suits drugs with meaningful clinical advantages in serious conditions. It requires less extensive preliminary evidence than Breakthrough designation.

Breakthrough Medicine targets therapies with substantial evidence of superiority. The designation provides enhanced regulatory engagement but requires demonstration of major advantage and no prior global registration.

RAID designation applies specifically to drugs developed with Saudi-based clinical trials. Companies planning substantial Saudi investment in clinical development should consider RAID for maximum regulatory support.

Early engagement with SFDA through pre-submission meetings helps clarify pathway eligibility. The SFDA Drug Sector accepts inquiries at [email protected] and designation requests at [email protected].

Frequently Asked Questions

Primary Sources

1. Saudi Food and Drug Authority. Guidance for Priority Review of Product Registration, Version 5.3. Issued February 11, 2024.
2. Saudi Food and Drug Authority. Breakthrough Medicine Program Guidance, Version 1.1. Issued October 26, 2023; Updated April 30, 2024.
3. Saudi Food and Drug Authority. Research and Investigational Drugs (RAID) Designation Guidance, Version 1.0. Issued April 2, 2026; Effective July 2, 2026.
4. Saudi Food and Drug Authority. SFDA Approves the Registration of Elrexfio for the Treatment of Adults with Multiple Myeloma. News release. July 2, 2026.
5. Saudi Food and Drug Authority. SFDA Approves Registration of Anktiva for the Treatment of Bladder and Lung Cancer. News release. June 15, 2026.
6. ClinicalTrials.gov. MagnetisMM-3: Study of Elranatamab (PF-06863135) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM). NCT04649359.
7. U.S. Food and Drug Administration. Expedited Programs for Serious Conditions—Drugs and Biologics. Guidance for Industry. May 2014.